Catalent, Inc. (NYSE:CTLT) Position Boosted by Readystate Asset Management LP

Readystate Asset Management LP increased its stake in Catalent, Inc. (NYSE:CTLT) by 52.7% in the 4th quarter, Holdings Channel reports. The firm owned 97,223 shares of the company’s stock after purchasing an additional 33,558 shares during the period. Readystate Asset Management LP’s holdings in Catalent were worth $4,368,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CTLT. Cetera Advisor Networks LLC grew its holdings in shares of Catalent by 7.1% during the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after purchasing an additional 130 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of Catalent by 18.0% during the first quarter. Private Advisor Group LLC now owns 2,957 shares of the company’s stock worth $328,000 after buying an additional 452 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in shares of Catalent by 125.8% during the first quarter. Panagora Asset Management Inc. now owns 12,979 shares of the company’s stock worth $1,439,000 after buying an additional 7,231 shares in the last quarter. Yousif Capital Management LLC grew its stake in Catalent by 2.0% in the first quarter. Yousif Capital Management LLC now owns 24,561 shares of the company’s stock valued at $2,724,000 after purchasing an additional 470 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Catalent by 1.8% in the first quarter. Dimensional Fund Advisors LP now owns 991,019 shares of the company’s stock valued at $109,904,000 after purchasing an additional 17,813 shares in the last quarter.

Catalent Stock Up 0.3 %

Shares of CTLT stock traded up $0.16 during midday trading on Wednesday, reaching $55.94. 1,942,903 shares of the stock were exchanged, compared to its average volume of 2,613,947. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The company’s 50 day moving average is $56.85 and its two-hundred day moving average is $48.11. Catalent, Inc. has a 1 year low of $31.45 and a 1 year high of $60.20. The firm has a market cap of $10.11 billion, a PE ratio of -8.23, a price-to-earnings-growth ratio of 6.05 and a beta of 1.20.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.62 earnings per share. On average, equities research analysts predict that Catalent, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on CTLT shares. UBS Group reiterated a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens reissued an “equal weight” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. StockNews.com initiated coverage on Catalent in a report on Thursday, April 11th. They issued a “sell” rating for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Finally, Barclays increased their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Catalent currently has an average rating of “Hold” and a consensus target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.